May 15 – 20, 2022
Casino Conference Centre
Europe/Prague timezone

SHINE Phase II of IV: a focus on Lu-177

May 17, 2022, 10:50 AM
Red Hall

Red Hall

Verbal Production and Application of Radionuclides Radionuclides Production & Application


Cory Hawkins (SHINE Technologies)


As part of a long-term vision to deploy fusion technology in a scalable path to practical fusion energy, SHINE Technologies has ventured to produce lutetium-177. While a one-of-kind Mo-99 production plant is being constructed, SHINE’s Therapeutics division is currently manufacturing small quantities of 177LuCl3 to support clinical studies for cancer radioligand therapy. SHINE expects a combination of technologies, including in-house target enrichment/recycling and non-reactor irradiation to be integrated into SHINE’s commercial Lu-177 production, which could help to mitigate the supply chain shortages and position SHINE to scale the process to hundreds of patient doses per batch. This presentation will introduce you to SHINE Technologies and provide an overview of the clinical Lu-177 process.

Primary author

Cory Hawkins (SHINE Technologies)

Presentation materials

There are no materials yet.